Image source: We Are Covert, SARS-CoV-2 illustration (04), marked as public domain

Adapt and overcome

Coronavirus evolving: How SARS-CoV-2 mutations could delay vaccine development

A new analysis of the worldwide effort to sequence the coronavirus genome has revealed the scale of the genetic changes that are occurring in the virus known as SARS-CoV-2, as it spreads across the world.

These changes have important implications for molecular diagnostics and potentially vaccine success. Led by the London School of Hygiene & Tropical Medicine (LSHTM), the research identified several mutations that show adaptation, where the virus has selected changes, probably as a result of improved ability for human transmission. These mutations could also impact whether vaccines or drugs will work to kill the virus.

The scientists published their findings at BioRxiv.

While mutations, or ‘viral variants’, are often seen in viruses, usually a result of tiny errors during the DNA replication process that do not change the virus ability to survive. The mutations identified by the LSHTM team are different in that they have occurred simultaneously around the world, indicating that they give the virus an advantage. Although it is not yet known wh at that advantage is, the researchers say that they should be monitored closely in case they affect therapies or vaccines to combat the virus or are making the virus more aggressive. If they are, diagnostics will need to adapt to detect them.

We have seen a few [variations] that look important to the virus and these could have important implications for diagnostics, vaccines and therapies

Martin Hibberd

Using a genetic analysis technique, the researchers analysed the genetic mutations across more than 5,000 viruses from around the world. They were looking for patterns of evolution which indicate that the virus may have adapted to its human host. They suggest the virus could now be classified into two groups with similar genetic material or ‘genetic clusters’. These different strains have different prevalence in individual countries, which may mean that diagnostics may have different performance in each country.

Professor Martin Hibberd from LSHTM said: “Overall, the virus does not seem to have mutated very much and most strains are relatively similar to each other. This suggests that the virus is well adapted to humans and is not changing rapidly. However, while the number of genetic variations at this stage of the pandemic were relatively small, we have seen a few that look important to the virus and these could have important implications for diagnostics, vaccines and therapies.”

Continued surveillance of the virus is required to track how it is adapting, and where in the world these adaptations are appearing, to monitor whether these mutations could also change the virus’ characteristics, and potentially virulence or transmissibility.


Source: London School of Hygiene & Tropical Medicine

12.05.2020

Read all latest stories

Related articles

Photo

Genetic

App analyses Covid-19 genome on a smartphone

A new mobile app has made it possible to analyse the genome of the SARS-CoV-2 virus on a smartphone in less than half an hour.

Photo

Coronavirus origins

Researchers crack COVID-19 genome signature

Using machine learning, a team of Western computer scientists and biologists have identified an underlying genomic signature for 29 different COVID-19 DNA sequences. This new data discovery tool will…

Photo

COVID-19 infections

Genetic network analysis provides 'snapshot' of pandemic origins

Researchers from Cambridge, UK, and Germany have reconstructed the early “evolutionary paths” of COVID-19 in humans – as infection spread from Wuhan out to Europe and North America – using…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Agena Bioscience - MassARRAY Colon Panel

Amplification/Detection

Agena Bioscience - MassARRAY Colon Panel

Agena Bioscience GmbH
Eppendorf – BioSpectrometer fluroescence

Research Use Only (RUO)

Eppendorf – BioSpectrometer fluroescence

Eppendorf AG
Eppendorf – μCuvette G1.0

Research Use Only (RUO)

Eppendorf – μCuvette G1.0

Eppendorf AG
Orion Diagnostica Oy – Orion GenRead

Amplification

Orion Diagnostica Oy – Orion GenRead

Orion Diagnostics Oy